Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/ttds4904

EVALUATING THE IMPACT OF TOFACITINIB IN A PATIENT WITH DOWN SYNDROME AND ALOPECIA AREATA: A CASE STUDY

Dr. Manisha Mishra[1], Dr. Parneet Kaur[1*], Dr. Shalabh Singla[2]

[1]Junior Resident, Department of Dermatology Venereology and Leprosy, Maharishi Markandeshwar Medical College and Hospital, Solan, Himachal Pradesh
[2]Senior Resident Department of Dermatology Venereology and Leprosy Maharishi Markandeshwar Medical College And Hospital, Solan, Himachal Pradesh

***Corresponding Author:** Dr Parneet Kaur
*Junior Resident, Dermatology Venereology And Leprosy, Maharishi Markandeshwar Medical College And Hospital Solan, Himachal Pradesh, Email: Chhina1996@gmail.com
Mobile: 9815769143

Abstract
Alopecia Areata (AA) has become an increasingly prevalent category of autoimmune illness wherein patients present with one or multiple areas of hair loss that are not scarring in nature and are linked to variations in immune function. Treating alopecia areata in patients with chromosomal abnormalities such as Down syndrome can prove to be extremely challenging. It thus becomes relevant to present a clinical case report of a 30-year-old male with Down's syndrome who was severely affected by alopecia areata which compromised his ability to function effectively. Although the patient has a genetic predisposition that limits previous treatments, standard methods to treat AA have failed in the subject. However, Tofacitinib, an oral Janus kinase (JAK) inhibitor, has increased popularity as a therapeutic option by virtue of its modulating effects on the immune system. The patient experienced significant regrowth of hair during the three-month follow up resulting in beautiful coverage and density of hair on the scalp. The studies indicate minimal to negative significant adverse effects, suggesting that tofacitinib had a favorable safety profile in treating alopecia areata in patients with Down syndrome. This emphasizes the necessity of individualized treatment for people with autoimmune disorders. These trials necessitate comprehensive further clinical investigations focusing on the safety, long-term hazards, and efficacy of tofacitinib in this patient demographic.

Keywords: Alopecia Areata, Down syndrome, Janus kinase inhibitors, Tofacitinib, Treatment efficacy, Autoimmune disorders

Introduction

Alopecia areata (AA) constitutes a chronic inflammatory autoimmune disorder primarily impacting hair follicles [1]. Alopecia areata, while not a severe hair loss disorder, seems to be immune-mediated [2]. The syndrome is characterized by the participation of cytotoxic T cells, an increase in proinflammatory cytokines [3], and a disruption in the JAK/STAT pathway, which is essential for immunological function [4]. It is essential to recognize that AA could develop at any age; nevertheless, the majority of cases are observed in children and adolescents, leading to adverse psychosocial effects on the patients [5,6].

The contemporary management of alopecia areata mostly involves topical corticosteroids and systemic immunosuppressants [7]; yet, responses are inconsistent, and no universally effective solution is acknowledged [8]. The oral use of tofacitinib, a selective JAK3 inhibitor, has shown effectiveness in adult patients with moderate to severe alopecia areata (AA) [9]. The clinical application of tofacitinib in the pediatric population is restricted; nevertheless [10], it has been authorized for juvenile idiopathic arthritis, and studies confirm its safety in children as young as 2 years old [11].

Trisomy 21, or Down syndrome (DS), is linked to the autoimmune disorder alopecia areata (AA) due to common autoimmunity and antibacterial characteristics associated with the condition [12]. This inclination is believed to stem from the IFN response, with its persistence partially ascribed to the heightened amount of IFN ligands in persons with DS [13], leading to excessive JAK/STAT activation [14]. Consequently, individuals with Down syndrome demonstrate increased levels of interferon-stimulated genes and modifications in their circulating proteome, signifying a condition of low-grade inflammation [15].

This case study seeks to assess the effects of tofacitinib treatment in a Down syndrome patient diagnosed with alopecia areata, offering insights into its therapeutic efficacy, safety, and potential to influence immunological dysregulation in this distinct patient group. The results could strengthen the existing evidence advocating for tailored strategies in the management of autoimmune disorders in individuals with hereditary syndromes.

Case Study

Mr. Sunil Kumar, a 30-year-old male with Down Syndrome, have been received to the dermatology outpatient department at M.M. Medical College and Hospital, Solan, with a primary complaint of subtotal alopecia areata, marked by significant hair loss (Figure 1). His medical history was ordinary, showing no indications of systemic disorders such as diabetes, hypertension, or other chronic ailments. The baseline vital signs were normal, and initial conservative interventions, such as dietary enhancement and topical corticosteroids, resulted in negligible improvement. A tiered treatment regimen was then implemented. Treatment Phase 1 involved administering oral tofacitinib at a dosage of 5 mg twice daily, leading to significant hair regrowth at the one-month follow-up (Figure 2). Treatment Phase 2 entailed the continuation of tofacitinib therapy, resulting in notable hair covering by the second follow-up (Figure 3). Phase 3 of the treatment focused on maintenance therapy with tofacitinib, leading to near-complete hair regrowth by the three-month follow-up (Figure 4). This case highlights the efficacy of tofacitinib in managing alopecia areata subtotalis in patients with Down Syndrome and underscores the importance of a multidisciplinary, phased treatment approach with regular follow-ups.



Fig 1: Patient with Alopecia Areata.



Fig 2: Patient evaluation following one month of Tofacitinib treatment to assess therapeutic impact.

Fig 3: Patient evaluation following two months of Tofacitinib treatment to assess therapeutic impact.



Fig 4: Patient evaluation following three months of Tofacitinib treatment to assess therapeutic impact.

Discussion

Alopecia areata (AA) remains an immune disorder associated with patchy hair loss that, at times, can inflict serious damage on the emotional and social well being of the patients [16]. Alopecia areata (AA) decreases under the authority of autoimmune discomforts which has shown promising response assists in it, in the form of the evolution of immunomodulatory medicines, specifically Janus kinase (JAK) inhibitors [17]. The case involving the application of Tofacitinib on a 30-year-old man with Down syndrome and extensive alopecia areata is consistent with the findings of more than a few studies that monitored the impact of Janus kinase (JAK) inhibitors on patients with autoimmune complications. Through admiration to these more personalized approaches the clinical results of hair regrowth for in cases of Tofacitinib treatment were pronounced with negligible side effects which further highlighted Tofacitinib as a prospective therapy in AA patients who are predisposed genetically.

Sardana et al., (2023) evaluated that Tofacitinib has a potential to cause remarkable hair resumption in patients suffering from severe alopecia areata as it has the capacity to block the JAK-STAT pathway and alter immune responses. This is consistent with our case data where Tofacitinib resulted in substantial restoration of scalp hair [18].

Similarly, Mackay-Wiggan et al. (2016) evaluated the use of Tofacitinib on individuals suffering from alopecia areata and reported significant improvements in hair density and coverage that mirror the findings of our case report. The study highlights the safety of the drug as crucial for any sustained treatment [19].

Conversely, Jamilloux et al., (2019) evaluated the application of JAK inhibitors in various autoimmune diseases, demonstrating yet even wider potential for their application. For the treatment of AA, special attention was paid to the drug tofacitinib, which enables the restoration of immune deregulation [20]. This study shows that it is suitable for patients with another genetic condition such as Down syndrome with considerable immune deregulation as well.

Nash et al., (2024), examined the double benefits of Tofacitinib in different autoimmune diseases and noted that the immunomodulatory actions are better than those demonstrated in AA, providing a rationale for treating other autoimmune diseases often seen in Down syndrome patients [21]. This remark strengthens our case, pointing out that the management strategy was not meant only for the treatment of AA rather it had wider general systemic benefits as well.

A longitudinal investigation of Crispin et al., (2016) undertaken on a pediatric and adult population has shown that Tofacitinib greatly improves hair regeneration rates at all levels of alopecia areata (AA) [22]. Their results confirm the efficacy of JAK inhibitors across the various age groups and disease severity such as in the significant response systemically seen in our patient.

The data emphasizes Tofacitinib as a targeted treatment in patients diagnosed with alopecia or a disorder characterized by hair loss and self-immune components such as Down syndrome as capable of producing regrowth of hair with minimal side effects. Tofacitinib is particularly effective in cases with complex co-morbidities and considerable improvement with very few side effects. These results require further studies to validate safety and efficacy of Tofacitinib, improve tailored therapeutic methods and extend its use into genetically predisposed populations.

Conclusion

In conclusion, the case study illustrates the effectiveness of tofacitinib, a Janus kinase inhibitor, in the treatment of alopecia areata (AA). The patient under question has Down syndrome (DS) and has effectively regenerated some of her hair with minimal negative effects. The immunological strategy advocating for targeted immunomodulation to address the autoimmune characteristics of alopecia areata in Down syndrome patients, whose therapeutic management has been largely overlooked, is also promising. However, the study possesses many drawbacks, including reliance on a single patient, a brief follow-up duration, and the absence of a control group, which constrains the external validity of the findings. Subsequent research should prioritize greater, multicenter trials with extended follow-up durations to validate these findings and assess the wider applicability of tofacitinib in autoimmune disorders linked to DS. Furthermore, a more comprehensive understanding of patient-specific responses to treatment and enhancements in treatment methods for DS patients diagnosed with AA could be achieved by investigating the underlying molecular and genetic causes of the disease.

References

1. Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: A multifactorial autoimmune condition. Journal of autoimmunity. 2019 Mar 1;98:74-85.
2. Mian M, Silfvast-Kaiser A, Paek S, Kivelevitch D, Menter A. A review of the most common dermatologic conditions and their debilitating psychosocial impacts. Int. Arch. Int. Med. 2019 Jul;3:018.
3. Nirenjen S, Narayanan J, Tamilanban T, Subramaniyan V, Chitra V, Fuloria NK, Wong LS, Ramachawolran G, Sekar M, Gupta G, Fuloria S. Exploring the contribution of pro-inflammatory cytokines to impaired wound healing in diabetes. Frontiers in immunology. 2023 Jul 27;14:1216321.
4. Tzeng HT, Chyuan IT, Lai JH. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential. Biochemical Pharmacology. 2021 Nov 1;193:114760.

5. Arns M, Kooij JS, Coogan AN. Identification and management of circadian rhythm sleep disorders as a transdiagnostic feature in child and adolescent psychiatry. Journal of the American Academy of Child & Adolescent Psychiatry. 2021 Sep 1;60(9):1085-95.
6. Liang XH, Yu AX, Bo XJ, Du DY, Su ZM. Metal/covalent-organic frameworks-based electrochemical sensors for the detection of ascorbic acid, dopamine and uric acid. Coordination Chemistry Reviews. 2023 Dec 15;497:215427.
7. Rantanen M, Karpechko AY, Lipponen A, Nordling K, Hyvärinen O, Ruosteenoja K, Vihma T, Laaksonen A. The Arctic has warmed nearly four times faster than the globe since 1979. Communications earth & environment. 2022 Aug 11;3(1):168.
8. Gupta AK, Carviel J, Abramovits W. Treating alopecia areata: current practices versus new directions. American journal of clinical dermatology. 2017 Feb;18:67-75.
9. Yan D, Fan H, Chen M, Xia L, Wang S, Dong W, Wang Q, Niu S, Rao H, Chen L, Nie X. The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies. Frontiers in Pharmacology. 2022 Aug 24;13:950450.
10. Soltani Khaboushan A, Yazdanpanah N, Rezaei N. Neuroinflammation and proinflammatory cytokines in epileptogenesis. Molecular neurobiology. 2022 Mar;59(3):1724-43.
11. Zhang H, Dhalla NS. The role of pro-Inflammatory cytokines in the pathogenesis of cardiovascular disease. International Journal of Molecular Sciences. 2024 Jan 16;25(2):1082.
12. Rachubinski AL, Estrada BE, Norris D, Dunnick CA, Boldrick JC, Espinosa JM. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Reports. 2019 Apr 1;5(4):365-7.
13. Thibaut R, Bost P, Milo I, Cazaux M, Lemaître F, Garcia Z, Amit I, Breart B, Cornuot C, Schwikowski B, Bousso P. Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nature cancer. 2020 Mar;1(3):302-14.
14. Snell LM, Brooks DG. New insights into type I interferon and the immunopathogenesis of persistent viral infections. Current opinion in immunology. 2015 Jun 1;34:91-8.
15. Waugh KA, Minter R, Baxter J, Chi C, Galbraith MD, Tuttle KD, Eduthan NP, Kinning KT, Andrysik Z, Araya P, Dougherty H. Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model. Nature genetics. 2023 Jun;55(6):1034-47.
16. Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clinical Reviews in Allergy & Immunology. 2021 Dec;61(3):403-23.
17. Morelli M, Scarponi C, Mercurio L, Facchiano F, Pallotta S, Madonna S, Girolomoni G, Albanesi C. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis. Journal of immunology research. 2018;2018(1):7897263.
18. Sardana K, Bathula S, Khurana A. Which is the Ideal JAK Inhibitor for Alopecia Areata–Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib-Revisiting the Immunomechanisms of the JAK Pathway. Indian Dermatology Online Journal. 2023 Jul 1;14(4):465-74.
19. Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI insight. 2016 Sep 9;1(15).
20. Sardana K, Bathula S, Khurana A. Which is the Ideal JAK Inhibitor for Alopecia Areata–Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib-Revisiting the Immunomechanisms of the JAK Pathway. Indian Dermatology Online Journal. 2023 Jul 1;14(4):465-74.
21. Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, Van Der Heijde D, Stoffer-Marx M, Takeuchi T. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the rheumatic diseases. 2021 Jan 1;80(1):71-87.
22. Crispin MK, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge MC, Marinkovich MP. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI insight. 2016 Sep 9;1(15).